VEGFA and gastric cancer: In a TST001 monotherapy dose-escalation study, one of three late-line GC patients who were heavily pretreated with multiple lines of treatment, including chemotherapy, programmed cell death protein 1 (PD-1)-targeted immunotherapy, and anti-vascular endothelial growth factor (VEGF) inhibitors, achieved a partial response after 6 weeks of treatment.